Search clinical trials for: Patidegib

Total 8 results

Sol-Gel Technologies, Ltd.
Premier Research Group plc

Recruiting

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Gorlin Syndrome

United States
PellePharm, Inc.

Completed

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Basal Cell Nevus Syndrome

United Kingdom
Sol-Gel Technologies, Ltd.

Terminated

Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)

Basal Cell Nevus Syndrome

United States, France, Belgium, Denmark, Germany, Italy, Netherlands, Spain, United Kingdom
PellePharm, Inc.

Completed

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas (BCC)

Basal Cell Carcinomas

United States
Sol-Gel Technologies, Ltd.

Terminated

An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Recurrent Basal Cell Carcinoma

United States
PellePharm, Inc.

Completed

Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)

Basal Cell Nevus Syndrome

United States, Spain, Germany, United Kingdom, Italy, France, Belgium, Canada, Denmark, Netherlands
Infinity Pharmaceuticals, Inc.

Completed

IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Chondrosarcoma | Basal Cell Carcinoma

United States
Hanmi Pharmaceutical Company Limited

Completed

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

Healthy

Korea, Republic of

3

Subscribe